Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11.

Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, Saripalli AL, Kryczek I, Wei S, Szeliga W, Vatan L, Stone EM, Georgiou G, Cieslik M, Wahl DR, Morgan MA, Chinnaiyan AM, Lawrence TS, Zou W.

Cancer Discov. 2019 Sep 25. pii: CD-19-0338. doi: 10.1158/2159-8290.CD-19-0338. [Epub ahead of print]

PMID:
31554642
2.

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA.

Cancer Res. 2019 Aug 1;79(15):3940-3951. doi: 10.1158/0008-5472.CAN-19-0761. Epub 2019 May 17.

PMID:
31101760
3.

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy.

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W.

Nature. 2019 May;569(7755):270-274. doi: 10.1038/s41586-019-1170-y. Epub 2019 May 1.

PMID:
31043744
4.

Spatial and phenotypic immune profiling of metastatic colon cancer.

Lazarus J, Maj T, Smith JJ, Perusina Lanfranca M, Rao A, D'Angelica MI, Delrosario L, Girgis A, Schukow C, Shia J, Kryczek I, Shi J, Wasserman I, Crawford H, Nathan H, Pasca Di Magliano M, Zou W, Frankel TL.

JCI Insight. 2018 Nov 15;3(22). pii: 121932. doi: 10.1172/jci.insight.121932.

5.

Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W.

Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24.

6.

Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis.

Crespo J, Wu K, Li W, Kryczek I, Maj T, Vatan L, Wei S, Opipari AW, Zou W.

J Immunol. 2018 Jul 15;201(2):814-820. doi: 10.4049/jimmunol.1700755. Epub 2018 May 25.

7.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

8.

High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas.

Butrym A, Kryczek I, Dlubek D, Jaskula E, Lange A, Jurczyszyn A, Mazur G.

Curr Probl Cancer. 2018 Mar - Apr;42(2):268-275. doi: 10.1016/j.currproblcancer.2018.01.006. Epub 2018 Jan 10.

PMID:
29456131
9.

miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer.

Yan TT, Ren LL, Shen CQ, Wang ZH, Yu YN, Liang Q, Tang JY, Chen YX, Sun DF, Zgodzinski W, Majewski M, Radwan P, Kryczek I, Zhong M, Chen J, Liu Q, Zou W, Chen HY, Hong J, Fang JY.

Cancer Res. 2018 Apr 1;78(7):1751-1765. doi: 10.1158/0008-5472.CAN-17-2101. Epub 2018 Jan 26.

10.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. Erratum in: J Clin Invest. 2018 Apr 2;128(4):1708.

11.

Phenotype and tissue distribution of CD28H+ immune cell subsets.

Crespo J, Vatan L, Maj T, Liu R, Kryczek I, Zou W.

Oncoimmunology. 2017 Aug 16;6(12):e1362529. doi: 10.1080/2162402X.2017.1362529. eCollection 2017.

12.

Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity.

Xia H, Wang W, Crespo J, Kryczek I, Li W, Wei S, Bian Z, Maj T, He M, Liu RJ, He Y, Rattan R, Munkarah A, Guan JL, Zou W.

Sci Immunol. 2017 Nov 17;2(17). pii: eaan4631. doi: 10.1126/sciimmunol.aan4631.

13.

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, Lyssiotis C, Liu JR, Kryczek I, Zou W.

Nat Immunol. 2017 Dec;18(12):1332-1341. doi: 10.1038/ni.3868. Epub 2017 Oct 30.

14.

Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy.

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, Chen Y, Chen H, Hong J, Zou W, Fang JY.

Cell. 2017 Jul 27;170(3):548-563.e16. doi: 10.1016/j.cell.2017.07.008.

15.

IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.

Fang M, Li Y, Huang K, Qi S, Zhang J, Zgodzinski W, Majewski M, Wallner G, Gozdz S, Macek P, Kowalik A, Pasiarski M, Grywalska E, Vatan L, Nagarsheth N, Li W, Zhao L, Kryczek I, Wang G, Wang Z, Zou W, Wang L.

Cancer Res. 2017 May 15;77(10):2735-2745. doi: 10.1158/0008-5472.CAN-16-1602. Epub 2017 Mar 1.

16.

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, Hurd A, Aicher TD, Toogood PL, Glick GD, Paulos CM, Zou W, Carter LL.

Oncoimmunology. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854. eCollection 2016.

17.

Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.

Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui T, Wei S, Liu Y, Wang Y, Vatan L, Szeliga W, Greenson JK, Roliński J, Zgodzinski W, Huang E, Tao K, Wang G, Zou W.

Oncoimmunology. 2016 Aug 12;5(8):e1105430. doi: 10.1080/2162402X.2015.1105430. eCollection 2016 Aug.

18.

Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.

Sun D, Lin Y, Hong J, Chen H, Nagarsheth N, Peng D, Wei S, Huang E, Fang J, Kryczek I, Zou W.

Oncoimmunology. 2015 Sep 2;5(8):e1082704. doi: 10.1080/2162402X.2015.1082704. eCollection 2016 Aug.

19.

Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.

Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanisławek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, Kryczek I.

Cancer Res. 2016 Jun 1;76(11):3156-65. doi: 10.1158/0008-5472.CAN-15-2528. Epub 2016 Apr 6.

20.

Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W.

Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.

21.

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L, Szeliga W, Dou Y, Owens S, Marquez V, Tao K, Huang E, Wang G, Zou W.

Cancer Res. 2016 Jan 15;76(2):275-82. doi: 10.1158/0008-5472.CAN-15-1938. Epub 2015 Nov 13.

22.

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, Chinnaiyan AM, Welling TH, Marquez V, Kotarski J, Wang H, Wang Z, Zhang Y, Liu R, Wang G, Zou W.

Nat Immunol. 2016 Jan;17(1):95-103. doi: 10.1038/ni.3313. Epub 2015 Nov 2.

23.

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, Zou W.

Nature. 2015 Nov 12;527(7577):249-53. doi: 10.1038/nature15520. Epub 2015 Oct 26.

24.

Myeloid cells in hepatocellular carcinoma.

Wan S, Kuo N, Kryczek I, Zou W, Welling TH.

Hepatology. 2015 Oct;62(4):1304-12. doi: 10.1002/hep.27867. Epub 2015 Jul 1. Review.

25.

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH.

Gastroenterology. 2014 Dec;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039. Epub 2014 Aug 30.

26.

Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor.

Mazur G, Butrym A, Kryczek I, Dlubek D, Jaskula E, Lange A, Kuliczkowski K, Jelen M.

PLoS One. 2014 May 23;9(5):e98194. doi: 10.1371/journal.pone.0098194. eCollection 2014.

27.

IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.

Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, Zgodzinski W, Majewski M, Wallner G, Fang J, Huang E, Zou W.

Immunity. 2014 May 15;40(5):772-784. doi: 10.1016/j.immuni.2014.03.010. Epub 2014 May 8.

28.

Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W.

Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.

29.

Th17 cells have stem cell-like features and promote long-term immunity.

Wei S, Zhao E, Kryczek I, Zou W.

Oncoimmunology. 2012 Jul 1;1(4):516-519.

30.

Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer.

Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET, Zou W.

Oncoimmunology. 2012 Mar 1;1(2):152-161.

31.

Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease.

Wilke CM, Wang L, Wei S, Kryczek I, Huang E, Kao J, Lin Y, Fang J, Zou W.

J Transl Med. 2011 Dec 16;9:217. doi: 10.1186/1479-5876-9-217.

32.

Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G, Zou W.

Cancer Res. 2012 Jan 15;72(2):420-9. doi: 10.1158/0008-5472.CAN-10-4627. Epub 2011 Nov 28.

33.

Bone marrow and the control of immunity.

Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, Wang G, Zou W.

Cell Mol Immunol. 2012 Jan;9(1):11-9. doi: 10.1038/cmi.2011.47. Epub 2011 Oct 24. Review.

34.

Human TH17 cells are long-lived effector memory cells.

Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W.

Sci Transl Med. 2011 Oct 12;3(104):104ra100. doi: 10.1126/scitranslmed.3002949.

35.

Dual biological effects of the cytokines interleukin-10 and interferon-γ.

Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W.

Cancer Immunol Immunother. 2011 Nov;60(11):1529-41. doi: 10.1007/s00262-011-1104-5. Epub 2011 Sep 15.

PMID:
21918895
36.

Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma.

Mazur G, Jaskuła E, Kryczek I, Dłubek D, Butrym A, Wróbel T, Lange A, Kuliczkowski K.

Folia Histochem Cytobiol. 2011;49(2):240-7.

37.

Antigen-presenting cell (APC) subsets in ovarian cancer.

Wilke CM, Kryczek I, Zou W.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):120-6. doi: 10.3109/08830185.2011.567362. Review.

PMID:
21557638
38.

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W.

Int J Cancer. 2012 Jan 1;130(1):29-39. doi: 10.1002/ijc.25967. Epub 2011 Apr 8.

39.

IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.

Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J, Chang A, Roliński J, Radwan P, Fang J, Wang G, Zou W.

J Immunol. 2011 Apr 1;186(7):4388-95. doi: 10.4049/jimmunol.1003251. Epub 2011 Feb 28.

40.

Th17 cells in cancer: help or hindrance?

Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W.

Carcinogenesis. 2011 May;32(5):643-9. doi: 10.1093/carcin/bgr019. Epub 2011 Feb 8. Review.

41.

Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.

Wu K, Kryczek I, Chen L, Zou W, Welling TH.

Cancer Res. 2009 Oct 15;69(20):8067-75. doi: 10.1158/0008-5472.CAN-09-0901. Epub 2009 Oct 13.

42.

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W.

Blood. 2009 Aug 6;114(6):1141-9. doi: 10.1182/blood-2009-03-208249. Epub 2009 May 21.

43.

FOXP3 defines regulatory T cells in human tumor and autoimmune disease.

Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W.

Cancer Res. 2009 May 1;69(9):3995-4000. doi: 10.1158/0008-5472.CAN-08-3804. Epub 2009 Apr 21.

44.

Endogenous IL-17 contributes to reduced tumor growth and metastasis.

Kryczek I, Wei S, Szeliga W, Vatan L, Zou W.

Blood. 2009 Jul 9;114(2):357-9. doi: 10.1182/blood-2008-09-177360. Epub 2009 Mar 16.

45.

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1761-70. Review.

PMID:
19273160
46.

Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.

Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W.

J Immunol. 2008 Nov 1;181(9):5842-6.

47.

Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.

Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT, Zou W.

J Immunol. 2008 Oct 1;181(7):4733-41.

48.

Regulatory T cells: a new frontier in cancer immunotherapy.

Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ.

Adv Exp Med Biol. 2008;622:255-60. doi: 10.1007/978-0-387-68969-2_20. Review. No abstract available.

PMID:
18546633
49.

Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.

Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W.

Cancer Res. 2007 Sep 15;67(18):8900-5.

50.

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.

Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, Herberman RB, Zou W.

Cancer Res. 2007 Aug 1;67(15):7487-94.

Supplemental Content

Loading ...
Support Center